Symbols / CELZ
CELZ Chart
About
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.33M |
| Enterprise Value | -664.75K | Income | -5.96M | Sales | 6.00K |
| Book/sh | 2.17 | Cash/sh | 2.08 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -1.29 | PEG | — |
| P/S | 1054.22 | P/B | 0.84 | P/C | — |
| EV/EBITDA | 0.11 | EV/Sales | -110.79 | Quick Ratio | 20.57 |
| Current Ratio | 20.71 | Debt/Eq | 0.25 | LT Debt/Eq | — |
| EPS (ttm) | -2.84 | EPS next Y | -1.40 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-07 16:00 | ROA | -59.68% |
| ROE | -98.14% | ROIC | — | Gross Margin | 60.00% |
| Oper. Margin | -1013.79% | Profit Margin | 0.00% | Shs Outstand | 3.49M |
| Shs Float | 2.38M | Short Float | 9.62% | Short Ratio | 2.28 |
| Short Interest | — | 52W High | 6.77 | 52W Low | 1.50 |
| Beta | 2.07 | Avg Volume | 95.68K | Volume | 7.17K |
| Target Price | $20.00 | Recom | Strong_buy | Prev Close | $1.82 |
| Price | $1.81 | Change | -0.82% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.00
Mean price target
2. Current target
$1.81
Latest analyst target
3. DCF / Fair value
$-19.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.81
Low
$20.00
High
$20.00
Mean
$20.00
- Creative Medical Tech (NASDAQ: CELZ) announces $4.2M warrant exercise; 2,790,340 warrants - Stock Titan Wed, 29 Oct 2025 07
- Creative Medical Technology Holdings, Inc. Achieves Milestone with WHO for Second INN Recognition of CELZ-101 - Quiver Quantitative ue, 10 Feb 2026 08
- Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ): When Will It Breakeven? - simplywall.st hu, 10 Jul 2025 07
- Two Creative Medical cell therapies gain WHO naming milestones - Stock Titan ue, 10 Feb 2026 08
- Companies Like Creative Medical Technology Holdings (NASDAQ:CELZ) Are In A Position To Invest In Growth - Yahoo Finance Sun, 27 Apr 2025 07
- Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating - Seeking Alpha Mon, 12 May 2025 07
- Creative Medical (CELZ) Price Target Reduced by Roth Capital | C - GuruFocus Wed, 04 Jun 2025 07
- Creative Medical Technology Holdings, Inc. Announces Immediate Exercise of Warrants and Issuance of New Warrants, Expected Proceeds of $4.2 Million - Quiver Quantitative Wed, 29 Oct 2025 07
- Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq ue, 25 Mar 2025 07
- Creative Medical (NASDAQ: CELZ) gets WHO INN 'olastrocel' for CELZ-201 cell therapy - Stock Titan ue, 02 Dec 2025 08
- Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) Shift From Loss To Profit - Yahoo Finance Sun, 16 Mar 2025 07
- Creative Medical Technology Holdings, Inc. Reports Positive Interim Results from CELZ-201 Clinical Trial for Chronic Lower Back Pain - Quiver Quantitative ue, 13 Jan 2026 08
- New cell therapy for chronic back pain reaches key milestone in clinical test - Stock Titan Wed, 17 Dec 2025 08
- CELZ Stock Price and Chart — NASDAQ:CELZ - TradingView Sat, 11 Feb 2023 08
- Creative Medical Technology Holdings, Inc. Reports 2025 Milestones and Strategic Advancements in Regenerative Medicine - Quiver Quantitative Mon, 27 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1500 | 8062 | — | Sale at price 5.00 - 5.75 per share. | FINGER MICHAEL H. | Director | — | 2025-02-19 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.63M | -5.53M | -10.15M | -3.03M |
| TotalUnusualItems | 0.00 | 26.62M | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 26.62M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.49M | -5.29M | -10.14M | 19.21M |
| ReconciledDepreciation | 110.45K | 94.58K | 92.08K | 92.08K |
| ReconciledCostOfRevenue | 4.40K | 3.60K | 28.49K | 47.95K |
| EBITDA | -5.63M | -5.53M | -10.15M | 23.58M |
| EBIT | -5.74M | -5.62M | -10.24M | 23.49M |
| NetInterestIncome | 250.38K | 333.56K | 100.33K | -4.28M |
| InterestExpense | 0.00 | 4.28M | ||
| InterestIncome | 250.38K | 333.56K | 100.33K | 0.00 |
| NormalizedIncome | -5.49M | -5.29M | -10.14M | -7.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.49M | -5.29M | -10.14M | 19.21M |
| TotalExpenses | 5.75M | 5.63M | 10.33M | 3.21M |
| TotalOperatingIncomeAsReported | -5.74M | -5.62M | -10.24M | -3.13M |
| DilutedAverageShares | 1.48M | 1.41M | 1.09M | 129.94K |
| BasicAverageShares | 1.48M | 1.41M | 1.09M | 104.20K |
| DilutedEPS | -3.71 | -3.76 | -9.28 | 140.25 |
| BasicEPS | -3.71 | -3.76 | -9.28 | 184.25 |
| DilutedNIAvailtoComStockholders | -5.49M | -5.29M | -10.14M | 19.21M |
| NetIncomeCommonStockholders | -5.49M | -5.29M | -10.14M | 19.21M |
| NetIncome | -5.49M | -5.29M | -10.14M | 19.21M |
| NetIncomeIncludingNoncontrollingInterests | -5.49M | -5.29M | -10.14M | 19.21M |
| NetIncomeContinuousOperations | -5.49M | -5.29M | -10.14M | 19.21M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -5.49M | -5.29M | -10.14M | 19.21M |
| OtherIncomeExpense | 26.62M | |||
| SpecialIncomeCharges | 0.00 | 585.60K | ||
| OtherSpecialCharges | -585.60K | |||
| GainOnSaleOfSecurity | 26.03M | |||
| NetNonOperatingInterestIncomeExpense | 250.38K | 333.56K | 100.33K | -4.28M |
| InterestExpenseNonOperating | 0.00 | 4.28M | ||
| InterestIncomeNonOperating | 250.38K | 333.56K | 100.33K | 0.00 |
| OperatingIncome | -5.74M | -5.62M | -10.24M | -3.13M |
| OperatingExpense | 5.75M | 5.63M | 10.30M | 3.17M |
| DepreciationAmortizationDepletionIncomeStatement | 110.45K | 94.58K | 92.08K | 92.08K |
| DepreciationAndAmortizationInIncomeStatement | 110.45K | 94.58K | 92.08K | 92.08K |
| Amortization | 110.45K | 94.58K | 92.08K | 92.08K |
| AmortizationOfIntangiblesIncomeStatement | 110.45K | 94.58K | 92.08K | 92.08K |
| ResearchAndDevelopment | 2.40M | 1.97M | 6.27M | 109.18K |
| SellingGeneralAndAdministration | 3.24M | 3.56M | 3.94M | 2.96M |
| GrossProfit | 6.60K | 5.40K | 60.11K | 39.80K |
| CostOfRevenue | 4.40K | 3.60K | 28.49K | 47.95K |
| TotalRevenue | 11.00K | 9.00K | 88.60K | 87.75K |
| OperatingRevenue | 11.00K | 9.00K | 88.60K | 87.75K |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 57.50K | ||
| OrdinarySharesNumber | 1.75M | 1.37M | 1.41M | 633.89K |
| ShareIssued | 1.75M | 1.43M | 1.41M | 633.89K |
| TangibleBookValue | 5.81M | 9.90M | 15.43M | 9.69M |
| InvestedCapital | 6.34M | 10.34M | 15.86M | 10.22M |
| WorkingCapital | 5.81M | 9.90M | 15.43M | 9.69M |
| NetTangibleAssets | 5.81M | 9.90M | 15.43M | 9.69M |
| CommonStockEquity | 6.34M | 10.34M | 15.86M | 10.22M |
| TotalCapitalization | 6.34M | 10.34M | 15.86M | 10.22M |
| TotalEquityGrossMinorityInterest | 6.34M | 10.34M | 15.86M | 10.22M |
| StockholdersEquity | 6.34M | 10.34M | 15.86M | 10.22M |
| TreasuryStock | 0.00 | 270.95K | 0.00 | |
| RetainedEarnings | -64.59M | -59.10M | -53.81M | -43.67M |
| AdditionalPaidInCapital | 70.93M | 69.71M | 69.68M | 53.88M |
| CapitalStock | 1.75K | 1.43K | 1.41K | 6.34K |
| CommonStock | 1.75K | 1.43K | 1.41K | 6.34K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 327.64K | 371.39K | 3.32M | 1.05M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 327.64K | 371.39K | 3.32M | 1.05M |
| PayablesAndAccruedExpenses | 327.64K | 371.39K | 3.32M | 1.05M |
| CurrentAccruedExpenses | 39.92K | 39.92K | 39.92K | 24.39K |
| Payables | 287.72K | 331.47K | 3.28M | 1.03M |
| DuetoRelatedPartiesCurrent | 14.19K | 14.19K | 14.19K | 264.19K |
| AccountsPayable | 273.53K | 317.28K | 3.27M | 761.86K |
| TotalAssets | 6.67M | 10.72M | 19.19M | 11.27M |
| TotalNonCurrentAssets | 533.84K | 444.29K | 438.88K | 530.96K |
| OtherNonCurrentAssets | 3.28K | 3.28K | 3.28K | 3.28K |
| GoodwillAndOtherIntangibleAssets | 530.56K | 441.01K | 435.60K | 527.68K |
| OtherIntangibleAssets | 530.56K | 441.01K | 435.60K | 527.68K |
| CurrentAssets | 6.14M | 10.27M | 18.75M | 10.74M |
| OtherCurrentAssets | 192.71K | 277.25K | 338.12K | |
| PrepaidAssets | 338.12K | 0.00 | ||
| Inventory | 2.19K | 6.59K | 10.19K | 10.87K |
| Receivables | 0.00 | 2.48K | ||
| AccountsReceivable | 0.00 | 2.48K | ||
| CashCashEquivalentsAndShortTermInvestments | 5.94M | 9.99M | 18.40M | 10.72M |
| OtherShortTermInvestments | 0.00 | 6.52M | 10.08M | 0.00 |
| CashAndCashEquivalents | 5.94M | 3.47M | 8.32M | 10.72M |
| CashEquivalents | 10.08M | 0.00 | ||
| CashFinancial | 5.94M | 3.47M | 8.32M | 10.72M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.50M | -8.13M | -7.80M | -2.22M |
| RepurchaseOfCapitalStock | -174.96K | -270.95K | 0.00 | -196.75K |
| RepaymentOfDebt | 0.00 | -5.96M | ||
| IssuanceOfDebt | 0.00 | 4.32M | ||
| IssuanceOfCapitalStock | 1.63M | 0.00 | 15.47M | 15.22M |
| CapitalExpenditure | -200.00K | -100.00K | ||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 9.19K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 5.94M | 3.47M | 8.32M | 10.72M |
| BeginningCashPosition | 3.47M | 8.32M | 10.72M | 98.01K |
| ChangesInCash | 2.47M | -4.85M | -2.40M | 10.63M |
| FinancingCashFlow | 1.45M | -270.95K | 15.47M | 12.84M |
| CashFlowFromContinuingFinancingActivities | 1.45M | -270.95K | 15.47M | 12.84M |
| NetOtherFinancingCharges | -548.31K | |||
| ProceedsFromStockOptionExercised | 0.00 | 457.00 | 0.00 | |
| NetPreferredStockIssuance | 100.00 | 0.00 | 0.00 | 265.25K |
| PreferredStockPayments | 0.00 | -196.75K | ||
| PreferredStockIssuance | 100.00 | 0.00 | 0.00 | 462.00K |
| NetCommonStockIssuance | 1.45M | -270.95K | 15.47M | 14.76M |
| CommonStockPayments | -174.96K | -270.95K | 0.00 | |
| CommonStockIssuance | 1.63M | 0.00 | 15.47M | 14.76M |
| NetIssuancePaymentsOfDebt | 0.00 | -1.63M | ||
| NetLongTermDebtIssuance | 0.00 | -1.63M | ||
| LongTermDebtPayments | 0.00 | -5.96M | ||
| LongTermDebtIssuance | 0.00 | 4.32M | ||
| InvestingCashFlow | 6.32M | 3.45M | -10.08M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 6.32M | 3.45M | -10.08M | 0.00 |
| NetInvestmentPurchaseAndSale | 6.52M | 3.55M | -10.08M | 0.00 |
| SaleOfInvestment | 6.52M | 26.40M | 0.00 | |
| PurchaseOfInvestment | 0.00 | -22.85M | -10.08M | 0.00 |
| NetIntangiblesPurchaseAndSale | -200.00K | -100.00K | 0.00 | 0.00 |
| PurchaseOfIntangibles | -200.00K | -100.00K | 0.00 | 0.00 |
| OperatingCashFlow | -5.30M | -8.03M | -7.80M | -2.22M |
| CashFlowFromContinuingOperatingActivities | -5.30M | -8.03M | -7.80M | -2.22M |
| ChangeInWorkingCapital | 45.09K | -2.84M | 2.19M | 249.47K |
| ChangeInPayablesAndAccruedExpense | -43.85K | -2.95M | 2.52M | 262.82K |
| ChangeInAccruedExpense | 0.00 | 15.54K | 20.64K | |
| ChangeInPayable | -43.85K | -2.95M | 2.51M | 242.18K |
| ChangeInAccountPayable | -43.85K | -2.95M | 2.51M | 410.96K |
| ChangeInPrepaidAssets | 84.54K | 108.20K | -338.12K | 0.00 |
| ChangeInInventory | 4.40K | 3.60K | 672.00 | -10.87K |
| ChangeInReceivables | 0.00 | 2.48K | -2.48K | |
| ChangesInAccountReceivables | 0.00 | 2.48K | -2.48K | |
| OtherNonCashItems | 4.16M | |||
| StockBasedCompensation | 36.65K | 36.65K | 68.75K | 595.38K |
| ProvisionandWriteOffofAssets | 0.00 | 93.82K | ||
| DepreciationAmortizationDepletion | 110.45K | 94.58K | 92.08K | 92.08K |
| DepreciationAndAmortization | 110.45K | 94.58K | 92.08K | 92.08K |
| AmortizationCashFlow | 110.45K | 94.58K | 92.08K | 92.08K |
| AmortizationOfIntangibles | 110.45K | 94.58K | 92.08K | 92.08K |
| OperatingGainsLosses | -34.09K | -26.62M | ||
| GainLossOnInvestmentSecurities | -34.09K | -26.03M | ||
| NetIncomeFromContinuingOperations | -5.49M | -5.29M | -10.14M | 19.21M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CELZ
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|